Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Sobanski, Esther [VerfasserIn]   i
 Dittmann, Ralf [VerfasserIn]   i
 Skopp, Gisela [VerfasserIn]   i
 Strohbeck-Kühner, Peter [VerfasserIn]   i
Titel:A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD
Verf.angabe:E. Sobanski, D. Sabljic, B. Alm, C. Baehr, R.W. Dittmann, G. Skopp, P. Strohbeck-Kuehner
Jahr:2012
Jahr des Originals:2011
Umfang:8 S.
Fussnoten:Published online ahead of print: 15 December 2011 ; Gesehen am 07.06.2018
Titel Quelle:Enthalten in: Pharmacopsychiatry
Ort Quelle:Stuttgart [u.a.] : Thieme, 1984
Jahr Quelle:2012
Band/Heft Quelle:45(2012), 03, Seite 100-107
ISSN Quelle:1439-0795
Abstract:Background: With the increasing recognition of adult attention-deficit/hyperactivity disorder (ADHD) there is an emerging need to investigate medication in this population. Methods: In this waiting list-controlled trial, 64 ADHD-patients (mean age 35.8±8.7 years) were randomly assigned to a daily dosage of up to 80 mg atomoxetine (Atx) or waiting list for 12-weeks. Primary outcome was the change of the observer-rated DSM-IV total ADHD score on the Conners’ Adult ADHD Rating Scales (CAARS-O:L DSM-IV total ADHD score) from baseline to endpoint. Other efficacy measures included self-rated CAARS-S:L DSM-IV total ADHD score, CAARS-O/S:L problems with self-concept and emotional lability score, Wender-Reimherr Adult Attention Deficit Disorder Scale Emotional Dysregulation Score, and General Activities Score on the Quality of Life Enjoyment and Satisfaction Questionnaire. Efficacy measures were analysed in the per-protocol population. Results: Mean change in CAARS:O-L DSM-IV total ADHD score was  - 13.1±7.7 in the Atx vs.  - 0.4±4.8 in the control group (p<0.005). Treatment response (≥30% reduction) was 60.1% in the Atx vs. 0% in the waiting list group. The other efficacy measures also showed significant improvements. The overall incidence of adverse events (AEs) was 70.4% in the Atx group, the most frequent included fatigue, irritability, nausea and decreased appetite. In Atx-treated patients 18.5% discontinued early due to AEs. Discussion: Our results suggest that Atx is an effective treatment in adult ADHD. It reduces ADHD core and associated emotional symptoms and increases self-esteem and quality of life. AEs were consistent with those reported in other studies in adult ADHD.
DOI:doi:10.1055/s-0031-1291319
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: http://dx.doi.org/10.1055/s-0031-1291319
 Volltext: http://www.thieme-connect.de.ezproxy.medma.uni-heidelberg.de/DOI/DOI?10.1055/s-0031-1291319
 DOI: https://doi.org/10.1055/s-0031-1291319
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1576163598
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68258783   QR-Code
zum Seitenanfang